Advanced Heart Failure and Transplant Cardiology

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 986

Special Issue Editor


E-Mail
Guest Editor
Heart Failure and Pulmonary Hypertension Unit, Hospital Alvaro Cunqueiro, Complexo Hospitalario Universitario de Vigo, Vigo, Spain
Interests: heart failure; pulmonary hypertension; ventricular assist devices

Special Issue Information

Dear Colleagues,

Heart failure (HF) is associated with increased morbidity and mortality. Different etiologies can cause HF, including congenital heart defects, coronary artery disease, and non-ischemic cardiomyopathies. Patients with HF have a reduced quality of life and suffer from chest pain, shortness of breath, fatigue, and cardiac arrhythmias. Treatment of HF involves pharmacotherapy, interventional cardiology, and cardiac surgery. Patients with HF often have cardiac arrhythmias requiring the implantation of cardiac devices such as pacemaker, ICD, or CRT systems. In advanced HF, temporary mechanical circulatory support or the permanent implantation of ventricular assist devices may be mandatory.

This Special Issue will contain a selection of papers highlighting the current challenges in heart failure and cardiac transplantation. We welcome the submission of original research (basic research or clinical research) and review manuscripts focusing on the diagnosis, risk factors, treatment, and prognosis of as well as novel approaches to cardiac arrhythmias, cardiac pacemakers, cardiac resynchronization therapy, cardiomyopathies, congenital heart defects, heart failure, heart transplantation, implantable cardioverter-defibrillators, mechanical circulatory support, and ventricular assist devices.

Dr. David Dobarro
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • heart transplantation
  • cardiology
  • ventricular assist devices

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 762 KiB  
Article
Destination Therapy Strategies of Advanced Heart Failure in Elderly Non-Heart Transplant Candidates: A Propensity Matching Analysis from the LEVO-D and REGALAD Registries
by David Dobarro, Sergio Raposeiras-Roubin, Luis Almenar-Bonet, Eduard Solé-González, Mireia Padilla-Lopez, Carles Diez-Lopez, Javier Castrodeza, Maria Dolores García-Cosío, Marta Cobo-Marcos, Javier Tobar, Pau Codina, Silvia Lopez-Fernandez, Francisco Pastor, Diego Rangel-Sousa, Eduardo Barge-Caballero, Beatriz Diaz-Molina, Alfredo Barrio-Rodriguez, Virginia Burgos-Palacios, Jesús Álvarez-García, Oscar González-Fernández, Andrés Grau-Sepulveda, José Manuel Garcia-Pinilla, Sonia Ruiz-Bustillo, Ana B. Mendez-Fernández, David Vaqueriza-Cubillo, Igor Sagasti-Aboitiz, Miguel Rodriguez-Santamarta, Ainara Lozano-Bahamonde, Ana Abecia, Inés Gómez-Otero, Raquel Marzoa, Eva González-Babarro, Manuel Gómez-Bueno and José Gonzalez-Costelloadd Show full author list remove Hide full author list
Life 2024, 14(12), 1570; https://doi.org/10.3390/life14121570 - 29 Nov 2024
Viewed by 807
Abstract
Heart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive HT or an LVAD, so alternative strategies are needed. Intermittent levosimendan can reduce [...] Read more.
Heart transplantation (HT) is the gold standard therapy for advanced heart failure (ADHF), and LVADs as destination therapy are an option in non-HT candidates. Most patients with ADHF never receive HT or an LVAD, so alternative strategies are needed. Intermittent levosimendan can reduce HF hospitalizations in ADHF patients in the short term. It is uncertain whether the results of the comparison of inotropes with older-generation LVADs would have the same outcomes in the current era of ADHF patients treated with levosimendan, who are less sick but older. In this paper, we compare the use of two therapeutic strategies for end-stage HF in patients who are not candidates for HT: repetitive intermittent levosimendan vs. LVAD as destination therapy. To do so, we compare two multicenter cohorts of real-life patients from Spain: the LEVO-D registry and the REGALAD registry. In total, 715 patients coming from the two registries were found: 403 from LEVO-D and 312 from REGALAD. Non-adjusted median survival was shorter for LEVO-D patients, with the benefit for the LVADs seen only after the first year of therapy. The survival advantage for the LVAD cohort was also true after analysis of the matched cohort but, as in the non-matched analysis, the survival benefit was mainly shown after one year of follow-up. We conclude that in elderly ADHF non-HT candidates, LVAD therapy offers significantly better long-term outcomes when compared to intermittent levosimendan; thus, it should be considered in carefully selected candidates. On the other hand, in poor LVAD candidates or highly comorbid patients, intermittent inotropic support with levosimendan could be a reasonable alternative to LVAD, as 1-year outcomes are similar. Full article
(This article belongs to the Special Issue Advanced Heart Failure and Transplant Cardiology)
Show Figures

Figure 1

Back to TopTop